Its immunology drug Dupixent is approved to ... Unlike many unprofitable biotech companies, Regeneron was in the “green” and generated $4.3 billion in net income in 2022.

attempts to track an index of companies in developed and emerging markets that focus on genomics, immunology, and bioengineering. It currently owns positions in 49 pharmaceutical and biotech ...

One takeaway from the ongoing biotech IPO drought is that companies should have at least ... development of a pipeline of inflammation and immunology (I&I) drugs, including a lead program that ...

Promising biotech companies could become attractive acquisition ... “Our main focus is our five key growth areas...immunology, oncology, neuroscience, aesthetics and eye care ...

The number of smid-cap biotech companies with market caps at or below ... Pfizer is launching several potential blockbusters in cancer and immunology. Data on Pfizer’s obesity-drug candidate ...

China is teeming with promising science in areas such as oncology and immunology ... comes not only from other VC firms or even biotech companies. It’s coming from big pharma, he said.

which specializes in immunology technology, where he was CEO for the past eight years. He has previous experience running divisions for major biotech companies in Asia. Curley, who co-founded the ...